vs
Side-by-side financial comparison of GAXOS.AI INC. (GXAI) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.
GAXOS.AI INC. is the larger business by last-quarter revenue ($1.2M vs $773.0K, roughly 1.6× Scinai Immunotherapeutics Ltd.). On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs 172.2%).
GXAI vs SCNI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $773.0K |
| Net Profit | $-957.9K | — |
| Gross Margin | — | — |
| Operating Margin | -99.0% | — |
| Net Margin | -77.2% | — |
| Revenue YoY | 94996.3% | 172.2% |
| Net Profit YoY | -15.1% | — |
| EPS (diluted) | $-0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $498.3K | — | ||
| Q2 25 | $171.0K | $773.0K | ||
| Q2 24 | $0 | $284.0K |
| Q4 25 | $-957.9K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q2 25 | $-749.4K | — | ||
| Q2 24 | $-809.2K | — |
| Q4 25 | -99.0% | — | ||
| Q3 25 | -263.9% | — | ||
| Q2 25 | -574.8% | — | ||
| Q2 24 | — | — |
| Q4 25 | -77.2% | — | ||
| Q3 25 | -201.0% | — | ||
| Q2 25 | -438.3% | — | ||
| Q2 24 | — | — |
| Q4 25 | $-0.13 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q2 24 | $-0.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $840.5K | $989.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $7.9M |
| Total Assets | $13.4M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $840.5K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $989.0K | ||
| Q2 24 | $4.5M | $3.1M |
| Q4 25 | $13.1M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $15.0M | $7.9M | ||
| Q2 24 | $4.7M | $-7.3M |
| Q4 25 | $13.4M | — | ||
| Q3 25 | $14.3M | — | ||
| Q2 25 | $15.4M | $11.8M | ||
| Q2 24 | $5.1M | $14.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-733.1K | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-733.1K | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $-716.9K | — | ||
| Q2 24 | $-738.5K | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
